Preliminary Final Report
Filed with ASX · · 65 pages · English
Summary by 6ix AI
The report highlights a revenue increase from ordinary activities, alongside a net loss attributable to members. The company is focusing on expanding its market presence, particularly in the United States, and has made significant progress towards FDA clearance for its pain assessment technology. PainChek continues to invest in research and development while achieving growth in its existing markets, with a notable increase in contracted licenses.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from PainChek
- Strongly Supported A$7.5m Placement to Drive Int. Growth
- Final US FDA De Novo Clearance Submission Completed
- PainChek Reports Strong Quarterly Sales Growth
- PainChek has productive final FDA De Novo clearance meeting
- PainChek partners with Eldermark to expand US market reach
Later from PainChek
- Compelling Clinical and Economic Results in Scottish Pilot
- Trading Halt
- PainChek FDA Cleared to Commence Sales in US$100M US Market
- PainChek Secures First US Customer Following FDA Clearance
- Response to ASX Aware Letter
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek